Oral sessions summaries


Aesthetic

A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Dynamic Forehead Lines Following Glabellar Line Injections

Jeremy B. Green, MD, FAAD

Expert commentary by Kimberly Butterwick, MD

AAD VMX 2020 - Oral session

View
Atopic Dermatitis

Lebrikizumab, a High-Affinity IL-13 Inhibitor, Demonstrates Rapid and Clinically Meaningful Improvements in Quality of Life Measures in a Phase 2b Trial of Moderate-to-Severe Atopic Dermatitis Patients

Emma Guttman-Yassky, MD, PhD

Expert commentary by Peter Lio, MD, FAAD

AAD VMX 2020 - Oral session

View
Atopic Dermatitis

Efficacy and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: Results from the Phase 3 JADE MONO-2 Study

Melinda Gooderham, MSc, MD, FRCPC

Expert commentary by Peter Lio, MD, FAAD

AAD VMX 2020 - Oral session

View
Bullous disease

Autoimmune Connective Tissue and Bullous Disease

Victoria P. Werth, MD

Expert commentary by Martina Lambertini, MD

AAD VMX 2020 - Oral session

View
Cancer Genome

Predicting Cancer Survival Outcomes of Anti-TNF, IL-17, and IL-23 using Gene Expression Data

Nikolai Klebanov, MD

Expert commentary by Christine J Ko, MD

AAD VMX 2020 - Oral session

View
Dermatopathology

What’s New in Dermatopathology: Translational Research

John T. Seykora, MD, PhD

Expert commentary by Christine J Ko, MD

AAD VMX 2020 - Oral session

View
Infections

What’s New in Dermatopathology: Infections

Travis W. Vandergriff, MD, FAAD

Expert commentary by Jules Lipoff, MD

AAD VMX 2020 - Oral session

View
Melanoma

Higher BMI is Associated with Increased Toxicity in Patients Undergoing Pembrolizumab Treatment for Advanced Melanoma

Surya Ravichandran, BS

Expert commentary by Martina Lambertini, MD

AAD VMX 2020 - Oral session

View
Pediatric

Pediatric Dermatology: Therapeutic and Diagnostic Pearls

Esteban Fernandez Faith, MD, FAAD

Expert commentary by Antonio Torrelo, MD

AAD VMX 2020 - Oral session

View
Pediatric

Pediatric Contact Dermatitis

Kari Martin, MD, FAAD

Expert commentary by Swen Malte John, MD, PhD

AAD VMX 2020 - Oral session

View
Pityriasis Rubra Pilaris

Pityriasis Rubra Pilaris Treated with Ixekizumab – An Open-Label Pilot Trial

Teri M. Greiling, MD, PhD

Expert commentary by Peter Lio, MD, FAAD

AAD VMX 2020 - Oral session

View
Polycystic Ovarian Syndrome

The Effect of Adding Combined Oral Contraceptives or Metformin to Laser Hair Removal Treatment on the Quality of Life of Polycystic Ovarian Patient with Hirsutism: A Randomized Control Trial

Nevine Dorgham, MD, PhD

Expert commentary by Shady Mahmoud Ibrahim, MD

AAD VMX 2020 - Oral session

View
Psoriasis

Risankizumab Versus Secukinumab in Patients with Moderate-to-Severe Plaque Psoriasis (IMMerge): A Phase 3 Trial

Richard B. Warren, BSc (Hons), MBChB (Hons), PhD

Expert commentary by Kirk Barber, MD 

AAD VMX 2020 - Oral session

View
Skin Microbiome

The Longitudinal Evolution of Skin Microbiome of Children from Birth to 10 Years of Age

Kimberly Capone, PhD

Expert commentary by Lisa M. Arkin, MD

AAD VMX 2020 - Oral session

View
Teledermatology

Making Teledermatology Work for You: How to Choose the Right Platform for You

Cory Simpson, MD, PhD, FAAD

Expert commentary by Jules Lipoff, MD

AAD VMX 2020 - Oral session

View
Vitiligo

Update on JAK Inhibition for Vitiligo

David Rosmarin, MD

Expert commentary by Aunna Pourang, MD

AAD VMX 2020 - Oral session

View